Regulation of soluble vascular endothelial growth factor receptor (sFlt-1/sVEGFR-1) expression and release in endothelial cells by human follicular fluid and granulosa cells

Ruth Gruemmer, Karin Motejlek, Daniela Berghaus, Herbert A Weich, Joseph Neulen, Ruth Gruemmer, Karin Motejlek, Daniela Berghaus, Herbert A Weich, Joseph Neulen

Abstract

Background: During the female reproductive cycle, follicular development and corpus luteum formation crucially depend on the fast generation of new blood vessels. The importance of granulosa cells and follicular fluid in controlling this angiogenesis is still not completely understood. Vascular endothelial growth factor (VEGF) produced by granulosa cells and secreted into the follicular fluid plays an essential role in this process. On the other hand, soluble VEGF receptor-1 (sFlt-1) produced by endothelial cells acts as a negative modulator for the bioavailability of VEGF. However, the regulation of sFlt-1 production remains to be determined.

Methods: We analyzed the influence of human follicular fluid obtained from FSH-stimulated women as well as of human granulosa cell conditioned medium on sFlt-1 production in and release from human umbilical vein endothelial cells (HUVEC) in vitro. Soluble Flt-1 gene expression was determined by RT-PCR analysis, amount of sFlt-1-protein was quantified by Sandwich-ELISA.

Results: Human follicular fluid as well as granulosa cell-conditioned medium significantly inhibit the production of sFlt-1 by endothelial cells on a posttranscriptional level. Treatment of cultured granulosa cells with either hCG or FSH had not impact on the production of sFlt-1 inhibiting factors. We further present data suggesting that this as yet unknown sFlt-1 regulating factor secreted by granulosa cells is not heat-sensitive, not steroidal, and it is of low molecular mass (< 1000 Da).

Conclusion: We provide strong support that follicular fluid and granulosa cells control VEGF availability by down regulation of the soluble antagonist sFlt-1 leading to an increase of free, bioactive VEGF for maximal induction of vessel growth in the ovary.

Figures

Figure 1
Figure 1
Proliferation of HUVECs incubated with culture medium containing 30% follicular fluid (+FF) or incubated with culture medium alone (control) for up to 4 days. From day 3 onwards a significant increase in cell number can be observed for those endothelial cells treated with follicular fluid compared to controls. * = p

Figure 2

Amount of sFlt-1 in the…

Figure 2

Amount of sFlt-1 in the culture supernatant of HUVECs treated with medium only…

Figure 2
Amount of sFlt-1 in the culture supernatant of HUVECs treated with medium only (grey bars) or with medium containing 30% human follicular fluid (FF, black bars) for up to 3 days. From day 2 onwards a significant increase in sFlt-1 content can be observed for those endothelial cells treated with medium only but not for those incubated with medium containing follicular fluid. * = p

Figure 3

Amount of sFlt-1 in the…

Figure 3

Amount of sFlt-1 in the culture supernatant of HUVECs after 4 days of…

Figure 3
Amount of sFlt-1 in the culture supernatant of HUVECs after 4 days of incubation with medium containing different concentrations of human follicular fluid. Amount of sFlt-1 decreases with increasing concentrations of follicular fluid showing a significant inhibition of sFlt-1 production at a concentration of 30%. * = p

Figure 4

Quantification of sFlt-1 in endothelial…

Figure 4

Quantification of sFlt-1 in endothelial cell culture supernatant. Neither heat inactivation of culture…

Figure 4
Quantification of sFlt-1 in endothelial cell culture supernatant. Neither heat inactivation of culture medium containing FCS (C2) nor absence of FCS (C3) has a measurable effect on sFlt-1 production of endothelial cells compared to incubation with untreated control medium containing FCS (C1). The significant inhibitory effect of untreated human follicular fluid (FF) on sFlt-1 production is maintained after ultra filtration leaving only molecules smaller than 1000 Dalton. This inhibition is not prevented neither by heat inactivation nor by charcoal treatment of the follicular fluid-flow through. All follicular fluids have been added to the culture medium at a concentration of 30%. * = p

Figure 5

RT-PCR of mRNA of HUVECs…

Figure 5

RT-PCR of mRNA of HUVECs incubated with medium only (C) or with medium…

Figure 5
RT-PCR of mRNA of HUVECs incubated with medium only (C) or with medium containing 30% follicular fluid (+FF). Densitometric evaluation revealed no significant difference in mRNA-expression of sFlt-1 between these two experimental groups at p

Figure 6

Amount of sFlt-1 in the…

Figure 6

Amount of sFlt-1 in the culture supernatant of HUVECs incubated for 4 days…

Figure 6
Amount of sFlt-1 in the culture supernatant of HUVECs incubated for 4 days with medium containing 30% granulosa cell (GC)-conditioned medium. Addition of GC-conditioned medium leads to a significant inhibition of sFlt-1 production of HUVECs (*). Treatment of granulosa cells with FCS or hCG during conditioning of medium has no influence on this inhibition. Incubation with follicular fluid (FF) of the same patients leads to a significant reduced production of sFlt-1 compared to controls as well as to treatment with GC-conditioned medium (**). p
Similar articles
Cited by
References
    1. Findlay JK. Angiogenesis in reproductive tissues. J Endocrinol. 1986;111:357–366. - PubMed
    1. Reynolds LP, Killilea SD, Redmer DA. Angiogenesis in the female reproductive system. FASEB J. 1992;6:886–892. - PubMed
    1. Augustin HG. Vascular morphogenesis in the ovary. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14:867–882. doi: 10.1053/beog.2000.0132. - DOI - PubMed
    1. Fraser HM, Wulff C. Angiogenesis in the primate ovary. Reprod Fertil Develop. 2001;13:557–566. doi: 10.1071/RD01055. - DOI - PubMed
    1. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, Marme D, Breckwoldt M. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metabol. 1995;80:1967–1971. doi: 10.1210/jc.80.6.1967. - DOI - PubMed
Show all 38 references
Publication types
MeSH terms
Substances
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Figure 2
Figure 2
Amount of sFlt-1 in the culture supernatant of HUVECs treated with medium only (grey bars) or with medium containing 30% human follicular fluid (FF, black bars) for up to 3 days. From day 2 onwards a significant increase in sFlt-1 content can be observed for those endothelial cells treated with medium only but not for those incubated with medium containing follicular fluid. * = p

Figure 3

Amount of sFlt-1 in the…

Figure 3

Amount of sFlt-1 in the culture supernatant of HUVECs after 4 days of…

Figure 3
Amount of sFlt-1 in the culture supernatant of HUVECs after 4 days of incubation with medium containing different concentrations of human follicular fluid. Amount of sFlt-1 decreases with increasing concentrations of follicular fluid showing a significant inhibition of sFlt-1 production at a concentration of 30%. * = p

Figure 4

Quantification of sFlt-1 in endothelial…

Figure 4

Quantification of sFlt-1 in endothelial cell culture supernatant. Neither heat inactivation of culture…

Figure 4
Quantification of sFlt-1 in endothelial cell culture supernatant. Neither heat inactivation of culture medium containing FCS (C2) nor absence of FCS (C3) has a measurable effect on sFlt-1 production of endothelial cells compared to incubation with untreated control medium containing FCS (C1). The significant inhibitory effect of untreated human follicular fluid (FF) on sFlt-1 production is maintained after ultra filtration leaving only molecules smaller than 1000 Dalton. This inhibition is not prevented neither by heat inactivation nor by charcoal treatment of the follicular fluid-flow through. All follicular fluids have been added to the culture medium at a concentration of 30%. * = p

Figure 5

RT-PCR of mRNA of HUVECs…

Figure 5

RT-PCR of mRNA of HUVECs incubated with medium only (C) or with medium…

Figure 5
RT-PCR of mRNA of HUVECs incubated with medium only (C) or with medium containing 30% follicular fluid (+FF). Densitometric evaluation revealed no significant difference in mRNA-expression of sFlt-1 between these two experimental groups at p

Figure 6

Amount of sFlt-1 in the…

Figure 6

Amount of sFlt-1 in the culture supernatant of HUVECs incubated for 4 days…

Figure 6
Amount of sFlt-1 in the culture supernatant of HUVECs incubated for 4 days with medium containing 30% granulosa cell (GC)-conditioned medium. Addition of GC-conditioned medium leads to a significant inhibition of sFlt-1 production of HUVECs (*). Treatment of granulosa cells with FCS or hCG during conditioning of medium has no influence on this inhibition. Incubation with follicular fluid (FF) of the same patients leads to a significant reduced production of sFlt-1 compared to controls as well as to treatment with GC-conditioned medium (**). p
Similar articles
Cited by
References
    1. Findlay JK. Angiogenesis in reproductive tissues. J Endocrinol. 1986;111:357–366. - PubMed
    1. Reynolds LP, Killilea SD, Redmer DA. Angiogenesis in the female reproductive system. FASEB J. 1992;6:886–892. - PubMed
    1. Augustin HG. Vascular morphogenesis in the ovary. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14:867–882. doi: 10.1053/beog.2000.0132. - DOI - PubMed
    1. Fraser HM, Wulff C. Angiogenesis in the primate ovary. Reprod Fertil Develop. 2001;13:557–566. doi: 10.1071/RD01055. - DOI - PubMed
    1. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, Marme D, Breckwoldt M. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metabol. 1995;80:1967–1971. doi: 10.1210/jc.80.6.1967. - DOI - PubMed
Show all 38 references
Publication types
MeSH terms
Substances
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Figure 3
Figure 3
Amount of sFlt-1 in the culture supernatant of HUVECs after 4 days of incubation with medium containing different concentrations of human follicular fluid. Amount of sFlt-1 decreases with increasing concentrations of follicular fluid showing a significant inhibition of sFlt-1 production at a concentration of 30%. * = p

Figure 4

Quantification of sFlt-1 in endothelial…

Figure 4

Quantification of sFlt-1 in endothelial cell culture supernatant. Neither heat inactivation of culture…

Figure 4
Quantification of sFlt-1 in endothelial cell culture supernatant. Neither heat inactivation of culture medium containing FCS (C2) nor absence of FCS (C3) has a measurable effect on sFlt-1 production of endothelial cells compared to incubation with untreated control medium containing FCS (C1). The significant inhibitory effect of untreated human follicular fluid (FF) on sFlt-1 production is maintained after ultra filtration leaving only molecules smaller than 1000 Dalton. This inhibition is not prevented neither by heat inactivation nor by charcoal treatment of the follicular fluid-flow through. All follicular fluids have been added to the culture medium at a concentration of 30%. * = p

Figure 5

RT-PCR of mRNA of HUVECs…

Figure 5

RT-PCR of mRNA of HUVECs incubated with medium only (C) or with medium…

Figure 5
RT-PCR of mRNA of HUVECs incubated with medium only (C) or with medium containing 30% follicular fluid (+FF). Densitometric evaluation revealed no significant difference in mRNA-expression of sFlt-1 between these two experimental groups at p

Figure 6

Amount of sFlt-1 in the…

Figure 6

Amount of sFlt-1 in the culture supernatant of HUVECs incubated for 4 days…

Figure 6
Amount of sFlt-1 in the culture supernatant of HUVECs incubated for 4 days with medium containing 30% granulosa cell (GC)-conditioned medium. Addition of GC-conditioned medium leads to a significant inhibition of sFlt-1 production of HUVECs (*). Treatment of granulosa cells with FCS or hCG during conditioning of medium has no influence on this inhibition. Incubation with follicular fluid (FF) of the same patients leads to a significant reduced production of sFlt-1 compared to controls as well as to treatment with GC-conditioned medium (**). p
Similar articles
Cited by
References
    1. Findlay JK. Angiogenesis in reproductive tissues. J Endocrinol. 1986;111:357–366. - PubMed
    1. Reynolds LP, Killilea SD, Redmer DA. Angiogenesis in the female reproductive system. FASEB J. 1992;6:886–892. - PubMed
    1. Augustin HG. Vascular morphogenesis in the ovary. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14:867–882. doi: 10.1053/beog.2000.0132. - DOI - PubMed
    1. Fraser HM, Wulff C. Angiogenesis in the primate ovary. Reprod Fertil Develop. 2001;13:557–566. doi: 10.1071/RD01055. - DOI - PubMed
    1. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, Marme D, Breckwoldt M. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metabol. 1995;80:1967–1971. doi: 10.1210/jc.80.6.1967. - DOI - PubMed
Show all 38 references
Publication types
MeSH terms
Substances
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Figure 4
Figure 4
Quantification of sFlt-1 in endothelial cell culture supernatant. Neither heat inactivation of culture medium containing FCS (C2) nor absence of FCS (C3) has a measurable effect on sFlt-1 production of endothelial cells compared to incubation with untreated control medium containing FCS (C1). The significant inhibitory effect of untreated human follicular fluid (FF) on sFlt-1 production is maintained after ultra filtration leaving only molecules smaller than 1000 Dalton. This inhibition is not prevented neither by heat inactivation nor by charcoal treatment of the follicular fluid-flow through. All follicular fluids have been added to the culture medium at a concentration of 30%. * = p

Figure 5

RT-PCR of mRNA of HUVECs…

Figure 5

RT-PCR of mRNA of HUVECs incubated with medium only (C) or with medium…

Figure 5
RT-PCR of mRNA of HUVECs incubated with medium only (C) or with medium containing 30% follicular fluid (+FF). Densitometric evaluation revealed no significant difference in mRNA-expression of sFlt-1 between these two experimental groups at p

Figure 6

Amount of sFlt-1 in the…

Figure 6

Amount of sFlt-1 in the culture supernatant of HUVECs incubated for 4 days…

Figure 6
Amount of sFlt-1 in the culture supernatant of HUVECs incubated for 4 days with medium containing 30% granulosa cell (GC)-conditioned medium. Addition of GC-conditioned medium leads to a significant inhibition of sFlt-1 production of HUVECs (*). Treatment of granulosa cells with FCS or hCG during conditioning of medium has no influence on this inhibition. Incubation with follicular fluid (FF) of the same patients leads to a significant reduced production of sFlt-1 compared to controls as well as to treatment with GC-conditioned medium (**). p
Similar articles
Cited by
References
    1. Findlay JK. Angiogenesis in reproductive tissues. J Endocrinol. 1986;111:357–366. - PubMed
    1. Reynolds LP, Killilea SD, Redmer DA. Angiogenesis in the female reproductive system. FASEB J. 1992;6:886–892. - PubMed
    1. Augustin HG. Vascular morphogenesis in the ovary. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14:867–882. doi: 10.1053/beog.2000.0132. - DOI - PubMed
    1. Fraser HM, Wulff C. Angiogenesis in the primate ovary. Reprod Fertil Develop. 2001;13:557–566. doi: 10.1071/RD01055. - DOI - PubMed
    1. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, Marme D, Breckwoldt M. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metabol. 1995;80:1967–1971. doi: 10.1210/jc.80.6.1967. - DOI - PubMed
Show all 38 references
Publication types
MeSH terms
Substances
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Figure 5
Figure 5
RT-PCR of mRNA of HUVECs incubated with medium only (C) or with medium containing 30% follicular fluid (+FF). Densitometric evaluation revealed no significant difference in mRNA-expression of sFlt-1 between these two experimental groups at p

Figure 6

Amount of sFlt-1 in the…

Figure 6

Amount of sFlt-1 in the culture supernatant of HUVECs incubated for 4 days…

Figure 6
Amount of sFlt-1 in the culture supernatant of HUVECs incubated for 4 days with medium containing 30% granulosa cell (GC)-conditioned medium. Addition of GC-conditioned medium leads to a significant inhibition of sFlt-1 production of HUVECs (*). Treatment of granulosa cells with FCS or hCG during conditioning of medium has no influence on this inhibition. Incubation with follicular fluid (FF) of the same patients leads to a significant reduced production of sFlt-1 compared to controls as well as to treatment with GC-conditioned medium (**). p
Similar articles
Cited by
References
    1. Findlay JK. Angiogenesis in reproductive tissues. J Endocrinol. 1986;111:357–366. - PubMed
    1. Reynolds LP, Killilea SD, Redmer DA. Angiogenesis in the female reproductive system. FASEB J. 1992;6:886–892. - PubMed
    1. Augustin HG. Vascular morphogenesis in the ovary. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14:867–882. doi: 10.1053/beog.2000.0132. - DOI - PubMed
    1. Fraser HM, Wulff C. Angiogenesis in the primate ovary. Reprod Fertil Develop. 2001;13:557–566. doi: 10.1071/RD01055. - DOI - PubMed
    1. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, Marme D, Breckwoldt M. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metabol. 1995;80:1967–1971. doi: 10.1210/jc.80.6.1967. - DOI - PubMed
Show all 38 references
Publication types
MeSH terms
Substances
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Figure 6
Figure 6
Amount of sFlt-1 in the culture supernatant of HUVECs incubated for 4 days with medium containing 30% granulosa cell (GC)-conditioned medium. Addition of GC-conditioned medium leads to a significant inhibition of sFlt-1 production of HUVECs (*). Treatment of granulosa cells with FCS or hCG during conditioning of medium has no influence on this inhibition. Incubation with follicular fluid (FF) of the same patients leads to a significant reduced production of sFlt-1 compared to controls as well as to treatment with GC-conditioned medium (**). p

References

    1. Findlay JK. Angiogenesis in reproductive tissues. J Endocrinol. 1986;111:357–366.
    1. Reynolds LP, Killilea SD, Redmer DA. Angiogenesis in the female reproductive system. FASEB J. 1992;6:886–892.
    1. Augustin HG. Vascular morphogenesis in the ovary. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14:867–882. doi: 10.1053/beog.2000.0132.
    1. Fraser HM, Wulff C. Angiogenesis in the primate ovary. Reprod Fertil Develop. 2001;13:557–566. doi: 10.1071/RD01055.
    1. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, Marme D, Breckwoldt M. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metabol. 1995;80:1967–1971. doi: 10.1210/jc.80.6.1967.
    1. Geva E, Jaffe RB. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril. 2000;74:429–438. doi: 10.1016/S0015-0282(00)00670-1.
    1. Abulafia O, Sherer DM. Angiogenesis of the ovary. Am J Obstet Gynecol. 2000;182:240–246.
    1. Cavender JL, Murdoch WJ. Morphological studies of the microcirculatory system of periovulatory ovine follicles. Biol Reprod. 1988;39:989–997.
    1. Hanahan K, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorogenesis. Cell. 1996;86:33–364. doi: 10.1016/S0092-8674(00)80108-7.
    1. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671–674. doi: 10.1038/386671a0.
    1. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS. 2005;94:209–231.
    1. Yan Z, Weich HA, Bernart W, Breckwoldt M, Neulen J. Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. J Clin Endocrinol Metabol. 1993;77:1723–1725. doi: 10.1210/jc.77.6.1723.
    1. Laitinen M, Ristimaki A, Honkasalo M, Narko K, Paavonen K, Ritvos O. Differential hormonal regulation of vascular endothelial growth factors VEGF, VEGF-B, and VEGF-C messenger ribonucleic acid levels in cultured human granulosa-luteal cells. Endocrinol. 1997;138:4748–4756. doi: 10.1210/en.138.11.4748.
    1. Otani N, Minami S, Yamoto M, Shikone T, Otani H, Nishiyama R, Otani T, Nakano R. The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy. J Clin Endocrinol Metabol. 1999;84:3845–3851. doi: 10.1210/jc.84.10.3845.
    1. Kamat BR, Brown LF, Manseau EJ, Senger DR, Dvorak HF. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol. 1995;146:157–165.
    1. Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm V, Hillan KJ, Schwall RH. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Med. 1998;4:336–340. doi: 10.1038/nm0398-336.
    1. Christenson LK, Stouffer RL. Follicle-stimulating hormone and luteinizing hormone/chorionic gonadotropin stimulation of vascular endothelial growth factor production by macaque granulosa cells from pre- and periovulatory follicles. J Clin Endocrinol Metab. 1997;82:2135–2142. doi: 10.1210/jc.82.7.2135.
    1. Neulen J, Raczek S, Pogorzelski M, Grunwald K, Yeo TK, Dvorak HF, Weich HA, Breckwoldt M. Secretion of vascular endothelial growth factor/vascular permeability factor from human luteinized granulosa cells is human chorionic gonadotrophin dependent. Mol Hum Reprod. 1998;4:203–206. doi: 10.1093/molehr/4.3.203.
    1. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Rev. 1997;18:4–25. doi: 10.1210/er.18.1.4.
    1. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 1993;90:10705–10709.
    1. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun. 1996;226:324–328. doi: 10.1006/bbrc.1996.1355.
    1. Hornig C, Weich HA. Soluble VEGF receptors. Angiogenesis. 1999;3:33–39. doi: 10.1023/A:1009033017809.
    1. Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest. 2000;80:443–454.
    1. McKeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol. 2004;191:1240–1246. doi: 10.1016/j.ajog.2004.03.004.
    1. Neulen J, Wenzel D, Hornig C, Wunsch E, Weissenborn U, Grunwald K, Buttner R, Weich H. Poor responder-high responder: the importance of soluble vascular endothelial growth factor receptor 1 in ovarian stimulation protocols. Hum Reprod. 2001;16:621–626. doi: 10.1093/humrep/16.4.621.
    1. Gruemmer R, Klein-Hitpass L, Neulen J. Regulation of gene expression in endothelial cells: the role of human follicular fluid. J Mol Endocrinol. 2005;34:37–46. doi: 10.1677/jme.1.01589.
    1. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, Lammoglia R, Charnock-Jones S. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod. 1998;59:1540–1548.
    1. Vuorela P, Helske S, Hornig C, Alitalo K, Weich H, Halmesmaki E. Amniotic fluid – soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol. 2000;95:353–357. doi: 10.1016/S0029-7844(99)00565-7.
    1. Dimitrakova ED, Dimitrakov JD, Karumanchi SG, Pehlivanov BK, Milchev NP, Dimitrakov DI. Placental soluble fms-like tyrosine-kinase-1 (sFlt-1) in pregnant women with preeclampsia. Folia Med (Plovdiv) 2004;46:19–21.
    1. Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epsein FH, Sibai BM, Suhhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–683. doi: 10.1056/NEJMoa031884.
    1. Seli E, Zeyneloglu HB, Senturk LM, Bahtiyar OM, Olive DL, Arici A. Basic fibroblast growth factor: peritoneal and follicular fluid levels and its effect on early embryonic development. Fertil Steril. 1998;69:1145–1148. doi: 10.1016/S0015-0282(98)00074-0.
    1. Koga K, Osuga Y, Tsutsumi O, Momoeda M, Suenaga A, Kugu K, Fujiwara T, Takai Y, Yano T, Taketani Y. Evidence for the Presence of Angiogenin in Human Follicular Fluid and the Up-Regulation of Its Production by Human Chorionic Gonadotropin and Hypoxia. J Clin Endocrinol Metab. 2000;85:3352–3335. doi: 10.1210/jc.85.9.3352.
    1. Krasnow JS, Berga SL, Guzick DS, Zeleznik AJ, Yeo KT. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report. Fertil Steril. 1996;65:552–555.
    1. Frederick JL, Shimanuki T, diZerega GS. Initiation of angiogenesis by human follicular fluid. Science. 1984;224:389–390.
    1. He Y, Smith SK, Day KA, Clark DE, Licence DR, Charnock-Jones DS. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol. 1999;13:537–545. doi: 10.1210/me.13.4.537.
    1. Huckle WR, Roche RI. Post-Transcriptional Control of Expression of sFlt-1, an Endogenous Inhibitor of Vascular Endothelial Growth Factor. J Cell Biochem. 2004;93:120–132. doi: 10.1002/jcb.20142.
    1. Krussel JS, Casan EM, Raga F, Hirchenhain J, Wen Y, Huang HY, Bielfeld P, Polan M. Expression of mRNA for vascular endothelial growth factor transmembranous receptors Flt1 and KDR, and the soluble receptor sFlt in cycling human endometrium. Mol Hum Reprod. 1999;5:452–458. doi: 10.1093/molehr/5.5.452.
    1. Redmer DA, Rone JD, Goodman AL. Evidence for a non-steroidal angiotropic factor from the primate corpus luteum: stimulation of endothelial cell migration in vitro. Proc Soc Exp Biol Med. 1985;179:136–140.

Source: PubMed

3
Subskrybuj